{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:20:43Z","timestamp":1778728843943,"version":"3.51.4"},"reference-count":37,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,5,8]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) in the phase 3 studies BE MOBILE 1 and 2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomised to subcutaneous bimekizumab 160\u2009mg or placebo every 4 weeks; from Week 16, all patients received bimekizumab 160\u2009mg every 4 weeks. We report the following outcomes to Week 52: Bath Ankylosing Spondylitis Functional Index (BASFI), Medical Outcomes Study Sleep Scale Revised (MOS-Sleep-R) Index II, Work Productivity and Activity Impairment: axSpA (WPAI:axSpA), Short Form-36 Physical and Mental Component Summary (SF-36 PCS\/MCS) and Ankylosing Spondylitis Quality of Life (ASQoL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At Week 16, bimekizumab-randomised patients demonstrated significantly greater improvement from baseline versus placebo in BASFI, SF-36 PCS and ASQoL (p&lt;0.001), and numerically greater improvements in MOS-Sleep-R Index II and WPAI:axSpA scores. Higher proportions of bimekizumab-randomised versus placebo-randomised patients at Week 16 achieved increasingly stringent thresholds for improvements in BASFI (0 to \u22644), and thresholds for meaningful improvements in SF-36 PCS (\u22655-point increase from baseline) and ASQoL (\u22654-point decrease from baseline). Responses were sustained or further improved to Week 52, where 60%\u201370% of bimekizumab-treated patients achieved BASFI \u22644\u2009and meaningful improvements in SF-36 PCS and ASQoL, regardless of whether originally randomised to bimekizumab or placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Bimekizumab treatment led to early improvements in physical function, sleep, work productivity and overall HRQoL at Week 16 in patients across the full axSpA disease spectrum. Improvements were sustained to Week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03928704\">NCT03928704<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03928743\">NCT03928743<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004202","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:48:42Z","timestamp":1717519722000},"page":"e004202","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Maureen","family":"Dubreuil","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands"},{"name":"Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-9176","authenticated-orcid":false,"given":"Karl","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospital NHS Trust, Norfolk, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vaux","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fleurinck","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma, Colombes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"M\u00f8rup","sequence":"additional","affiliation":[{"name":"UCB Pharma, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[{"name":"University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"2025090312443988000_10.2.e004202.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"2025090312443988000_10.2.e004202.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2025090312443988000_10.2.e004202.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"key":"2025090312443988000_10.2.e004202.4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2025090312443988000_10.2.e004202.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00194-8"},{"key":"2025090312443988000_10.2.e004202.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev125"},{"key":"2025090312443988000_10.2.e004202.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025090312443988000_10.2.e004202.8","doi-asserted-by":"crossref","first-page":"vi10","DOI":"10.1093\/rheumatology\/key217","article-title":"The current standard of care and the unmet needs for axial spondyloarthritis","volume":"57","author":"Noureldin","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312443988000_10.2.e004202.9","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030270","article-title":"The use of Janus kinase inhibitors in axial spondyloarthritis: current insights","volume":"15","author":"Toussirot","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025090312443988000_10.2.e004202.10","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1097\/RHU.0000000000001544","article-title":"Pain and fatigue in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: multinational real-world findings","volume":"27","author":"Strand","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2025090312443988000_10.2.e004202.11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14712598.2022.2156283","article-title":"Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis","volume":"23","author":"Braun","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025090312443988000_10.2.e004202.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with Bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2025090312443988000_10.2.e004202.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"2025090312443988000_10.2.e004202.14","first-page":"0519","article-title":"Long-term safety and efficacy of Bimekizumab in patients with active Ankylosing Spondylitis: 5-year results from a phase 2B study and its open-label extension","volume":"75","author":"Deodhar","year":"2023","journal-title":"Arthritis Rheumatology"},{"key":"2025090312443988000_10.2.e004202.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"2025090312443988000_10.2.e004202.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208642"},{"key":"2025090312443988000_10.2.e004202.17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheumatol"},{"key":"2025090312443988000_10.2.e004202.18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2025090312443988000_10.2.e004202.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"2025090312443988000_10.2.e004202.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2025090312443988000_10.2.e004202.21","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-9-36","article-title":"Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness therapy-fatigue subscale for patients with ankylosing spondylitis","volume":"9","author":"Revicki","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"2025090312443988000_10.2.e004202.22","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-021-00311-3","article-title":"The development and validation of a revised version of the medical outcomes study sleep scale (MOS Sleep-R)","volume":"5","author":"Yarlas","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2025090312443988000_10.2.e004202.23","unstructured":"Maruish ME . User\u2019s Guide for the MOS Sleep Scale\u2013Revised. Lincoln, RI: QualityMetric Incorporated, 2012."},{"key":"2025090312443988000_10.2.e004202.24","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2025090312443988000_10.2.e004202.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep457"},{"key":"2025090312443988000_10.2.e004202.26","unstructured":"Maruish ME . User\u2019s Manual for the SF-36v2 Health Survey. 3rd edn. Lincoln, RI: QualityMetric Incorporated, 2011."},{"key":"2025090312443988000_10.2.e004202.27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"2025090312443988000_10.2.e004202.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"2025090312443988000_10.2.e004202.29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11136-020-02686-0","article-title":"Validation of the ankylosing spondylitis quality of life assessment tool in patients with non-radiographic axial spondyloarthritis","volume":"30","author":"Hoepken","year":"2021","journal-title":"Qual Life Res"},{"key":"2025090312443988000_10.2.e004202.30","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/rheumatology\/keab901","article-title":"Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results","volume":"61","author":"Poddubnyy","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312443988000_10.2.e004202.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090242"},{"key":"2025090312443988000_10.2.e004202.32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002663","article-title":"Work participation in patients with axial spondyloarthritis: high prevalence of negative workplace experiences and long-term work impairment","volume":"9","author":"Kiltz","year":"2023","journal-title":"RMD Open"},{"key":"2025090312443988000_10.2.e004202.33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003468","article-title":"Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis","volume":"9","author":"Rudwaleit","year":"2023","journal-title":"RMD Open"},{"key":"2025090312443988000_10.2.e004202.34","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002912","article-title":"Sleep behaviour differs in women and men with psoriatic arthritis and axial spondyloarthritis with impact on quality of life and depressive symptoms","volume":"9","author":"Frede","year":"2023","journal-title":"RMD Open"},{"key":"2025090312443988000_10.2.e004202.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203967"},{"key":"2025090312443988000_10.2.e004202.36","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial spondyloarthritis","volume":"51","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312443988000_10.2.e004202.37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40744-021-00306-y","article-title":"Cross-walk of the assessment of spondyloarthritis international society health index and ankylosing spondylitis quality of life scores in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients","volume":"8","author":"Pike","year":"2021","journal-title":"Rheumatol Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:44:49Z","timestamp":1756928689000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,4]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/rmdopen-2024-004202"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004202","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}